KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Return on Sales (2019 - 2025)

Historic Return on Sales for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 0.37%.

  • Esperion Therapeutics' Return on Sales rose 2400.0% to 0.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 2100.0%. This contributed to the annual value of 0.01% for FY2024, which is 18300.0% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Return on Sales stood at 0.37%, which was up 2400.0% from 0.16% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Return on Sales registered a high of 0.42% during Q1 2024, and its lowest value of 11.4% during Q1 2021.
  • Its 5-year average for Return on Sales is 2.3%, with a median of 1.78% in 2023.
  • In the last 5 years, Esperion Therapeutics' Return on Sales skyrocketed by 313300bps in 2021 and then crashed by -24600bps in 2022.
  • Esperion Therapeutics' Return on Sales (Quarter) stood at 4.48% in 2021, then soared by 33bps to 3.02% in 2022, then skyrocketed by 41bps to 1.78% in 2023, then soared by 83bps to 0.3% in 2024, then fell by -22bps to 0.37% in 2025.
  • Its last three reported values are 0.37% in Q3 2025, 0.16% for Q2 2025, and 0.64% during Q1 2025.